Abstract
Matrix Metalloproteinases (MMPs) are zinc-containing proteinases that are responsible for the metabolism of extracellular matrix proteins. Overexpression of MMPs has been associated with a wide range of pathological diseases such as arthritis, cancer, multiple sclerosis and Alzheimers disease. The excessive and unregulated activity of Matrix Metalloproteinases type 2 (MMP-2), also known as gelatinase A, has been identified in a numbers of cancer metastases. Several MMP inhibitors (MMPi) have been proposed in the literature aiming to interfere in the MMPs activity. In this work we performed long MD simulations in order to study the dynamical behavior of the binding pocket S1 in the apo forms of MMP type 2 and 3, and identify, at the molecular level, the structural properties relevant for the designing of specific inhibitor of MMP-2.
Keywords: Matrix metalloproteinse, molecular dynamics, S1' binding pocket, MMP-2, MMP-3, metalloproteinase inhibitor
Current Pharmaceutical Design
Title: Molecular Dynamics Simulations of Metalloproteinases Types 2 and 3 Reveal Differences in the Dynamic Behavior of the S1 Binding Pocket
Volume: 13 Issue: 34
Author(s): Cesar Augusto F. de Oliveira, Maurice Zissen, John Mongon and J. Andrew Mccammon
Affiliation:
Keywords: Matrix metalloproteinse, molecular dynamics, S1' binding pocket, MMP-2, MMP-3, metalloproteinase inhibitor
Abstract: Matrix Metalloproteinases (MMPs) are zinc-containing proteinases that are responsible for the metabolism of extracellular matrix proteins. Overexpression of MMPs has been associated with a wide range of pathological diseases such as arthritis, cancer, multiple sclerosis and Alzheimers disease. The excessive and unregulated activity of Matrix Metalloproteinases type 2 (MMP-2), also known as gelatinase A, has been identified in a numbers of cancer metastases. Several MMP inhibitors (MMPi) have been proposed in the literature aiming to interfere in the MMPs activity. In this work we performed long MD simulations in order to study the dynamical behavior of the binding pocket S1 in the apo forms of MMP type 2 and 3, and identify, at the molecular level, the structural properties relevant for the designing of specific inhibitor of MMP-2.
Export Options
About this article
Cite this article as:
de Oliveira F. Cesar Augusto, Zissen Maurice, Mongon John and Mccammon Andrew J., Molecular Dynamics Simulations of Metalloproteinases Types 2 and 3 Reveal Differences in the Dynamic Behavior of the S1 Binding Pocket, Current Pharmaceutical Design 2007; 13 (34) . https://dx.doi.org/10.2174/138161207782794211
DOI https://dx.doi.org/10.2174/138161207782794211 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Mogroside V Inhibits Hyperglycemia-induced Lung Cancer Cells Metastasis through Reversing EMT and Damaging Cytoskeleton
Current Cancer Drug Targets Role of Erlotinib in Influencing the Quality of Life of Cancer Patients
Clinical Cancer Drugs Meet Our Editorial Board Member
Current Protein & Peptide Science Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy
Current Medicinal Chemistry <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Editorial [Hot Topic: Overview of Antiangiogenic Therapies in Hematological Malignancies (Guest Editor: D. Ribatti)]
Current Cancer Drug Targets Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Potential MicroRNA Targets for Cancer Chemotherapy
Current Medicinal Chemistry CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Current Pharmaceutical Design Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design Potential Roles of Eosinophils in Cancer Therapy: Epidemiological Studies, Experimental Models, and Clinical Pathology
Recent Patents on Anti-Cancer Drug Discovery Molecular Imaging Probe Development Using Microfluidics
Current Organic Synthesis